Company Overview and News
KUALA LUMPUR (Sept 21): Dufu Technology Corp Bhd shares traded 5.13% early today after it proposed a one-for-two bonus issue involving the issuance of up to 87.74 million bonus shares, to enhance the marketability and trading liquidity of its shares.
KUALA LUMPUR (Sep 20): Based on corporate announcements and news flow today, stocks in focus for Friday (Sep 21) may include the following: Scientex Bhd, Malaysia Smelting Corp Bhd, Eco World International Bhd, Pos Malaysia Bhd, AWC Bhd, Wong Engineering Corp Bhd, Dufu Technology Corp Bhd, Selangor Properties Bhd, SCGM Bhd and Pan Malaysia Corp Bhd.
4634 1783 SGPBY 7233
KUALA LUMPUR (Aug 14): The FBM KLCI struggled to recoup some lost ground in the morning session today amid some choppy trading.
7047 BATS 4162 5246 5202 9334 6033 7233 2852 5029 PNADF 5347 5225 7668 6645 TNABY TNABF Q0F IHHHF PNAGF
Dufu Technology Corp Bhd (-ve) Trading of the shares in Dufu Technology Corp Bhd (fundamental: 3/3, valuation: 1.8/3) triggered our momentum algorithm as the share price surged by 8.64% or 14 sen to close at RM1.76 with about 7.71 million shares traded. Its market capitalisation stood at RM286.4 million.
KUALA LUMPUR (Aug 7): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Dufu Technology Corp Bhd, Frontken Corp Bhd, Tien Wah Press Holdings Bhd, Hartalega Holdings Bhd, Uzma Bhd, Inta Bina Group Bhd, Metronic Global Bhd, Advancecon Holdings Bhd, Three-A Resources Bhd, KKB Engineering Bhd, Versatile Creative Bhd and MISC Bhd.
0012 4995 5347 TNABY TNABF 5168 7374 9466 0043 7233 HRGHY
KUALA LUMPUR (Aug 7): Dufu Technology Corp Bhd saw its second quarter ended June 30, 2018 (2QFY18) net profit rise by 72% to RM11.81 million, from RM6.88 million a year ago, due to higher demand for Hard Disk Drives (HDD) components and favourable foreign exchange effect thanks to the strengthening of the US dollar.
BSMAF 7233 1818
KUALA LUMPUR (July 18): RHB Retail Research said Dufu Technology Bhd may rebound further after it tested 94 sen support recently.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...